Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 158 Jul 28 – Oct 25, 2026
- Disclosed funding
- $6B 122 disclosed amounts
- Median round
- $24M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| MT Metagen TherapeuticsCompany profile A clinical-stage biotechnology company developing microbiome-based therapies using fecal microbiota transplantation. A clinical-stage biotechnology company developing microbiome-based therapies using fecal microbiota transplantation. | ¥190M | Series B extension (first close)Series B | Biotech | Japan | Investors | |
| S Science4BeautyCompany profile A Polish skincare company using a recombinant conotoxin active ingredient in anti-wrinkle creams and other products sold directly to consumers and through aesthetic-medicine channels. A Polish skincare company using a recombinant conotoxin active ingredient in anti-wrinkle creams and other products sold directly to consumers and through aesthetic-medicine channels. | PLN 7M | Series A | Biotech | Poland | Investors | |
| SM Superluminal MedicinesCompany profile Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity. Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity. | $60M | Series B | Biotech | United States | Investors | |
| T TensiveCompany profile Clinical-stage bioresorbable implants designed to support natural breast-tissue regeneration and mark the tumour bed after lumpectomy. Clinical-stage bioresorbable implants designed to support natural breast-tissue regeneration and mark the tumour bed after lumpectomy. | ≤€20M | Convertible venture debtUndisclosed | Biotech, Healthtech | Italy | Investors | |
| ST SiccaNova TherapeuticsCompany profile A biotechnology company developing an oral drug candidate for dry mouth and related gland-function disorders. A biotechnology company developing an oral drug candidate for dry mouth and related gland-function disorders. | ¥1.3B | Series A | Biotech | Japan | Investors | |
| TT Typewriter TherapeuticsCompany profile Typewriter Therapeutics is developing an all-RNA gene-writing platform that inserts therapeutic genes at a defined genomic site without viral vectors or double-strand DNA breaks. Its programs target in vivo engineered CAR-T cells and gene insertion for severe genetic diseases, including liver disorders. Typewriter Therapeutics is developing an all-RNA gene-writing platform that inserts therapeutic genes at a defined genomic site without viral vectors or double-strand DNA breaks. Its programs target in vivo engineered CAR-T cells and gene insertion for severe genetic diseases, including liver disorders. | $56M | Series A | Biotech | United States | Investors | |
 DorothCompany profile Doroth develops lab-on-a-chip molecular tests and monitoring services that help agricultural businesses detect plant pathogens and track biological crop treatments closer to where decisions are made. Doroth develops lab-on-a-chip molecular tests and monitoring services that help agricultural businesses detect plant pathogens and track biological crop treatments closer to where decisions are made. | $4.5M | Funding roundUndisclosed | Biotech, Agritech | Brazil | Investors | |
| D DataHowCompany profile DataHow builds DataHowLab, a process-modeling and digital-twin platform for biopharmaceutical process engineers and manufacturers. DataHow builds DataHowLab, a process-modeling and digital-twin platform for biopharmaceutical process engineers and manufacturers. | Undisclosed | Bridge financingUndisclosed | Biotech, Enterprise software | Switzerland | Investors | |
| NT NovaGo TherapeuticsCompany profile NovaGo Therapeutics is a clinical-stage biotech developing anti-Nogo-A antibodies intended to promote nerve regeneration and functional recovery after central nervous system injury. NovaGo Therapeutics is a clinical-stage biotech developing anti-Nogo-A antibodies intended to promote nerve regeneration and functional recovery after central nervous system injury. | CHF 24M | Series B | Biotech | Switzerland | Investors | |
| AT Amyl TherapeuticsCompany profile Amyl Therapeutics is developing immunotherapies that target amyloid aggregates linked to neurodegenerative disease. Amyl Therapeutics is developing immunotherapies that target amyloid aggregates linked to neurodegenerative disease. | €8.3M | Series A extensionSeries A | Biotech | Belgium | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jul 28, 2026
- 1Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
10rounds0led - 2RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
9rounds3led - 3Y Combinator (YC)
Molagri, Sensible Biotechnologies, WonderTx
6rounds0led - 4Catalio Capital Management
BigHat Biosciences, Basecamp Research, Enveda
6rounds2led - 5Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
5rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.